• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

    7/22/25 8:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RADX alert in real time by email

    SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB).

    Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine.

    Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology.

    Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI).

    Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy.

    "Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies," said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. "We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline."

    About Radiopharm Theranostics

    Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

    Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

    For more information:

    Investors:

    Riccardo Canevari

    CEO & Managing Director

    P: +1 862 309 0293

    E: [email protected]

    Anne Marie Fields

    Precision AQ

    (Formerly Stern IR)

    E: [email protected]

    Media:

    Matt Wright

    NWR Communications

    P: +61 451 896 420

    E: [email protected]

    Follow Radiopharm Theranostics:

    Website – https://radiopharmtheranostics.com/

    Twitter – https://twitter.com/TeamRadiopharm  

    Linked In – https://www.linkedin.com/company/radiopharm-theranostics/

    InvestorHub – https://investorhub.radiopharmtheranostics.com/



    Primary Logo

    Get the next $RADX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RADX

    DatePrice TargetRatingAnalyst
    3/12/2025$15.00Buy
    B. Riley Securities
    More analyst ratings

    $RADX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Radiance Medical with a new price target

    B. Riley Securities initiated coverage of Radiance Medical with a rating of Buy and set a new price target of $15.00

    3/12/25 7:30:55 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RADX
    SEC Filings

    View All

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    10/22/25 7:18:17 PM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    10/20/25 6:46:19 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    10/7/25 6:26:12 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RADX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

    Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from solid tumors, confirming proof-of-concept with Phase 2 topline results expected by H1 2026First cohort of patients in Phase 1 clinical trial of RAD 202 (HER2) shows higher than expected tumour uptake; Anticipates second cohort of patients to be fully enrolled with data available by year-end 2025Data from first six patients in Phase 1 clinical trial of RAD 204 (PDL-1) show promising tumor uptake, stable disease at the first dose level in two out of three patientsData from Phase 1 study with RAD 301 supports decision to advance to Phase 2 imaging trial in patients with

    10/20/25 8:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan

    RAD has received firm commitments for a A$35 million capital raising via an institutional private placement to new Australian and international institutional and sophisticated investors at A$0.03 per ordinary shareLantheus continues support as strategic investor with A$7.6 million investment in the placement, increasing its shareholding to 14.5%Share Purchase Plan for existing eligible shareholders in Australia and New Zealand to raise a further A$5 million (approx.) at A$0.03 per shareParticipants in the Placement and the Share Purchase Plan will receive one (1) free attaching option for every one (1) new share subscribed for under the offer, with an exercise price of A$0.039 and expiration

    10/20/25 7:30:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 'HEAT' Dose Escalation Clinical Trial

    SYDNEY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 75mCi in the Phase 1 ‘HEAT' clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors. The DSMC is a multidisciplinary committee that conducts detailed reviews

    10/1/25 8:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RADX
    Leadership Updates

    Live Leadership Updates

    View All

    Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

    SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He w

    7/22/25 8:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care